Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 181 results for transplantation

  1. Robot-assisted kidney transplant (IPG609)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  2. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  3. Improving consent rates:- What are the key components of an intervention to improve consent rates?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  4. The experience of consenting for organ donation:- Does a positive experience of approach and process of consent for families increase consent rates?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  5. Improving rates of identification and referral of potential donors:- What are the key components of an intervention to improve identification and referral rates?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  6. Extracorporeal albumin dialysis for acute liver failure (IPG316)

    Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.

  7. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  8. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

  9. Reasons for refusal for consent:- Why do families refuse to give permission for organ donation?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  10. Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)

    Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.

  11. Haematological cancers: improving outcomes (NG47)

    This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.

  12. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    treatment with, for example, high-dose therapy and autologous stem cell transplantation. Many factors are likely to influence outcome,...

  13. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

  14. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.